Engineered immune cells take aim at stubborn autoimmune disease
Disease control
Not yet recruiting
This early-phase study tests a new cell therapy called universal STAR-T cells in people with autoimmune diseases that cause dangerously low platelet counts. About 6 adults aged 18-65 will receive a single infusion of these engineered cells to see if they are safe and can help con…
Phase: PHASE1 • Sponsor: Jian Zhu • Aim: Disease control
Last updated May 22, 2026 13:52 UTC